Mode
Text Size
Log in / Sign up
Phase 2 Completed N=151 Randomized Triple-blind Treatment

Study to Investigate the Analgesic Efficacy of a Single Dose of AZD1940

Source: ClinicalTrials.gov NCT00659490 ↗
Enrolled (actual)
151
Serious AEs
0.0%
Results posted
Mar 2012
Primary outcomePrimary: Pain Area Under the Curve 0-8h (AUC0-8h) — 355; 356; 129 mm*h

Summary

The primary aim of this study is to investigate if AZD1940 can relieve the pain induced by the surgical removal of one lower wisdom-tooth. This will be done by comparing the effect of AZD1940 to placebo ("inactive substance") on pain. A number of patients will instead receive the common painkiller naproxen for comparison purposes. Rescue medication, acetaminophen, will be allowed if a need for additional painkillers would arise. A number of patients will receive Naproxen as control.

Outcome Measures

OutcomeResultp-value
PRIMARY
Pain Area Under the Curve 0-8h (AUC0-8h)
355; 356; 129
SECONDARY
Pain Area Under the VAS Versus Time Curve 0-4h (AUC0-4h)
145; 143; 54
SECONDARY
Maximum Pain Based on VAS Scale
66; 65; 33
SECONDARY
Mean Pain Based on a VAS Scale
31; 29; 13
SECONDARY
Pain at Jaw Movement AUC0-8h
342; 337; 135
SECONDARY
Pain at Jaw Movement AUC0-4h
142; 138; 53
SECONDARY
Maximum Pain at Jaw Movement
63; 63; 33
SECONDARY
Mean Pain at Jaw Movement
32; 28; 14
SECONDARY
Pain at Rescue Medication
73; 70; 47
SECONDARY
Pain at Jaw Movement at Time of First Rescue Medication
67; 65; 53
SECONDARY
Time to First Intake of Rescue Medication.
3.8; 3.7; 4.7
SECONDARY
Number of Patients Requesting Rescue Medication
37; 43; 7
SECONDARY
Maximum Deterioration in Visual Analogue Mood Scale (VAMS) Stimulated
22; 26; 28
SECONDARY
Maximum Deterioration in VAMS High
30; 12; 20
SECONDARY
Maximum Deterioration in VAMS Anxious
20; 15; 13
SECONDARY
Maximum Deterioration in VAMS Sedated
33; 21; 24
SECONDARY
Maximum Deterioration in VAMS Down
20; 25; 24
SECONDARY
Time to Max Deterioration in VAMS Stimulated
143; 163; 213
SECONDARY
Time to Max Deterioration in VAMS High
115; 191; 193
SECONDARY
Time to Max Deterioration in VAMS Anxious
126; 167; 212
SECONDARY
Time to Max Deterioration in VAMS Sedated
190; 221; 227
SECONDARY
Time to Max Deterioration in VAMS Down
227; 262; 349

Eligibility Criteria

Inclusion Criteria

  • Patients scheduled for surgical removal of one partial or complete impacted mandibular third molar.
  • Provision of signed informed consent.
  • Healthy males or non-fertile females.

Exclusion Criteria

  • History of somatic disease/condition, which may interfere with the objectives of the study, as judged by the investigator.
  • History of previous or ongoing psychiatric disease/condition including psychosis, affective disorder, anxiety disorder, borderline state and personality disorder according to the criteria in the Diagnostic and Statistical Manual of Mental Disorder, 4th edition.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00659490). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search